鉅子生物(02367.HK)公佈年度業績 經調整淨利潤增長46.5% 研發支出同比增長42.1%
格隆匯3月26日丨鉅子生物(02367.HK)公吿，截至2024年12月31日止年度，公司收入55.39億元人民幣，同比增長57.2%；歸屬於母公司持有者盈利20.62億元，同比增長42.1%；年內經調整淨利潤（非《國際財務報吿準則》衡量指標）21.5億元，同比增長46.5%。董事會建議派發末期股息每股普通股人民幣0.6021元，建議派發特別股息每股普通股人民幣0.5921元。
收入增長的主要原因是報吿期內公司持續擴充產品品類，深耕線上和線下渠道、鞏固明星單品的增長以及成功推出新品並加強營銷，使得產品和品牌影響力進一步提升，銷售收入實現較快增長。
公司以科學技術為發展基石，持續加大研發投入，全方位牢築技術護城河。報吿期內，公司研發支出達到人民幣106.5百萬元，同比增長42.1%，研發支出佔收入比例1.9%。截至報吿期末，公司擁有188項在研項目。截至報吿期末，公司已獲授權及申請中專利達到167項，其中報吿期內新增74項。
報吿期內，公司順利推進III類醫療器械產品的研發和臨牀申報工作，獲得骨修復材料III類醫療器械註冊證，注射用重組膠原蛋白填充劑產品被予以優先審批。未來公司將繼續以技術為基，面向人民的重大需求，不懈努力，力爭實現更多的突破。
截至報吿期末，公司的產品進入約1,700家公立醫院，約3,000傢俬立醫院和診所，約650個連鎖藥房品牌和約6,000家CS/KA門店。
報吿期內，公司在主要電商平台均取得較快增長，可復美和可麗金的線上全渠道GMV增速在2024年618大促期間分別超過60%和100%，在2024年雙十一大促期間分別超過80%和150%，體現出消費者對公司旗下品牌的喜愛和公司電商團隊的運營成效。
展望2025年，公司將繼續堅持「樹品牌、拓渠道、強報批」的重點方向，推進各項工作和公司綜合實力的提升。公司將加大研發投入，積累技術儲備，做好三類醫療器械產品的臨牀申報審批工作。公司將打磨更多好的產品和系列，洞察並滿足更多的細分需求，豐富旗下品牌的內涵。公司將加大在主力品牌的營銷推廣力度，實現更大範圍的破圈，並培育孵化新品牌，為護膚品業務邁上下一個台階打基礎、做儲備。公司將逐步啟動對三類醫療器械商業化的準備工作，做好市場教育和培訓，賦能集團的第二成長曲線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
